Lomotil Solution

Quick links to important sections

Lomotil Solution

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lomotil Solution

Property Description
Active Ingredients Diphenoxylate HCl and Atropine Sulfate
Form Oral Solution (Liquid)
Pharmacological Class Opioid Receptor Agonist (Antidiarrheal)
Common Use Symptomatic control of diarrhea
Origin Synthetic

Lomotil Solution is a prescription combination medication formulated as an oral solution (liquid form), primarily used for the symptomatic management of diarrhea in patients aged 13 and older. The solution form is often prescribed to facilitate easier administration, particularly for children and individuals who have difficulty swallowing tablets.

The medicine contains two active pharmaceutical ingredients: diphenoxylate hydrochloride and a sub-therapeutic amount of atropine sulfate. This dual composition is a key differentiating factor, with the atropine component included to discourage potential misuse of the drug.


What Type of Medicine is Lomotil Solution and How is it Classified?

Lomotil Solution is classified based on its main constituent, diphenoxylate, which functions as a synthetic compound belonging to the opioid receptor agonist pharmacological class. Specifically, diphenoxylate is utilized as an antidiarrheal agent that exerts its effects locally on the smooth muscle of the intestines.

The unique combination with atropine, a mild anticholinergic agent, ensures the formulation adheres to safety guidelines. Diphenoxylate is considered a motility-reducing agent for controlling acute diarrhea, distinguishing it as a fast-acting agent in its class.


What is the Main Therapeutic Purpose of Lomotil Solution?

The primary therapeutic purpose of this solution is the effective symptomatic control of acute and chronic diarrhea. The action of the active ingredients slows the movement of contents through the gut, which in turn facilitates increased reabsorption of water and electrolytes.

This motility-reducing effect significantly leads to a reduction in the frequency of bowel movements and an improvement in stool consistency. It is essential to understand that Lomotil Solution is designed only to manage the external symptoms of diarrhea, providing relief while the underlying cause is addressed.

What side effects are possible with Lomotil Solution?

Possible Side Effects and Safety Information

The safety profile of Lomotil Solution, which combines diphenoxylate hydrochloride and atropine sulfate, is defined by effects across multiple body systems, as documented in regulatory sources.


Adverse Reaction Groupings

The official labeling documents adverse reactions primarily by the system-organ class they affect. While numerical frequencies (such as 'common' or 'rare') are generally not specified, effects are grouped into the following categories:

  • Nervous System Disorders: Reactions may include drowsiness, sedation, dizziness, or headache.
  • Psychiatric Disorders: Potential effects include euphoria, confusion, or restlessness.
  • Gastrointestinal Disorders: Documented effects include nausea, vomiting, abdominal cramps, and anorexia. The risk of paralytic ileus is also recognized.
  • Atropine-Related Effects: Effects associated with the anticholinergic component include dryness of the skin and mucous membranes, flushing, and tachycardia (rapid heart rate).
  • Immune System Disorders: Serious allergic reactions, including anaphylaxis and angioedema, have been reported.

Serious Safety Considerations and Restrictions

Official regulatory documents emphasize specific, clinically significant risks and safety constraints:

  • Serious Gastrointestinal Complications: The medication carries a risk of inducing toxic megacolon, particularly in patients with acute ulcerative colitis. It is contraindicated in diarrhea caused by enterotoxin-producing bacteria or pseudomembranous enterocolitis.
  • Absolute Pediatric Contraindication: The solution is strictly contraindicated for use in children under 6 years of age due to the risk of severe and potentially fatal respiratory and central nervous system depression.
  • Hepatic Impairment: Extreme caution is required when administered to patients with abnormal liver function or hepatorenal disease due to the potential risk of precipitating hepatic coma.
  • CNS Depressant Interaction: Concomitant use with other CNS depressants, such as alcohol or tranquilizers, may potentiate the depressant effects, as noted in the official label.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of Lomotil Solution, which contains diphenoxylate and atropine sulfate, presents a risk of dual toxicity encompassing both opioid and anticholinergic effects. The most critical manifestation is severe respiratory depression, which is often delayed for 12 to 30 hours after ingestion, posing a life-threatening risk of coma, permanent brain damage, and death.

Clinical manifestations documented in regulatory labeling include CNS symptoms such as somnolence, confusion, and seizures (opioid-related) alongside anticholinergic signs like tachycardia, restlessness, dry skin, and pupil dilation (mydriasis). Due to the high risk of delayed onset, it is officially mandated to seek immediate medical attention for any known or suspected overdose, even if the patient appears asymptomatic.

The required emergency intervention involves the administration of the specific opioid antagonist Naloxone to counteract respiratory depression; repeated doses are necessary due to diphenoxylate’s long duration of effect. Regulatory guidance requires continuous observation for at least 48 hours in a hospital setting to monitor for symptom relapse. There are explicit warnings that pediatric patients are at a heightened risk of severe toxicity and fatal outcomes, emphasizing the need for immediate, professional care.

Therapeutic Uses of Lomotil Solution

Quick Facts

  • Approved use: Management of diarrhea.
  • Therapeutic role: Used as an adjunctive treatment.

Lomotil (diphenoxylate and atropine sulfate) oral solution is a prescription medication utilized in the management of diarrhea. It is specifically indicated for use as adjunctive therapy in patients aged 13 years and older.

Main Uses and Therapeutic Benefits

The principal therapeutic benefit of this oral solution is to help reduce the occurrence and frequency of diarrhea. The medication is an approved treatment to help regulate bowel activity and may lead to a decrease in the number of stools. It is typically used as additional therapy along with necessary measures, such as appropriate fluid and electrolyte replacement, which are essential components of diarrhea care.

This agent is often reserved for situations where first-line approaches have not sufficiently addressed the condition, and clinical assessment determines its use is appropriate.

Eligibility and Restrictions for Use

The official eligibility profile for Lomotil Solution is strictly defined by regulatory age restrictions, underlying conditions, and physiological status.

Populations for Whom Use is Approved or Prohibited

Classification Eligibility Status Affected Population
Approved Use Allowed Patients 13 years of age and older only.
Absolute Contraindication Prohibited Pediatric patients less than 6 years of age.
Contraindication Prohibited Patients with obstructive jaundice.
Contraindication Prohibited Patients with diarrhea caused by specific enterotoxin-producing bacteria (e.g., C. difficile) or pseudomembranous enterocolitis.

Condition-Specific Restrictions

Use requires extreme caution in patients with advanced hepatorenal disease and in those with abnormal liver function; therapy must be discontinued promptly if abdominal distention occurs in patients with acute ulcerative colitis.

Age and Physiological Status

Safety and efficacy are not established in children younger than 13 years of age. The medicine is not recommended for children under 2 years of age. The solution must be withheld if severe dehydration or electrolyte imbalance is present. Caution should be exercised during pregnancy (use only if benefits justify risk) and lactation (excretion in breast milk is known).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Lomotil Solution primarily establishes constraints based on pharmacodynamic and pharmacokinetic interactions.


Documented Interaction Classifications

Interaction Type Interacting Agents Official Restriction/Outcome
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to the theoretical risk of a hypertensive crisis.
Pharmacodynamic (PD) Risk CNS Depressants (e.g., alcohol, opioids, sedatives) Use is advised against; leads to additive CNS depression and potentiated effects.
Pharmacokinetic (PK) Risk Antacids (e.g., aluminum hydroxide) May reduce absorption and systemic exposure of Lomotil Solution.
PK/PD Risk Anticholinergic Agents May increase the risk of severe anticholinergic effects due to the atropine component.

Population and General Constraints

Co-administration with interacting drugs requires extreme caution in patients with advanced hepatorenal disease or abnormal liver function. Drug accumulation in these populations may precipitate hepatic coma. The official regulatory label notes that elderly patients are more susceptible to both CNS depressant and anticholinergic effects, which heightens the clinical significance of pharmacodynamic interactions. No mandatory timing separation rules for co-administered products are explicitly documented.

Mechanism of Action

Mechanism of Action: Gastrointestinal Modulation

Modulation of Intestinal Nerve Signals The primary active component acts as an agonist on mu-opioid receptors found within the enteric nervous system (ENS) of the gut. This interaction dampens the release of neurotransmitters, which decreases the neurotransmitter release that mediates intestinal propulsive activity and initiates the mechanistic cascade of slowed movement.

Regulation of Gut Motility and Transit Time Reduced nerve signaling significantly decreases the frequency and force of intestinal smooth muscle contractions (peristalsis). The secondary ingredient, acting as an antagonist at muscarinic acetylcholine receptors, further promotes muscle relaxation. This combined effect prolongs the transit time of contents through the gastrointestinal tract, enabling a system-level physiological consequence.

Altered Fluid and Electrolyte Transport The extended duration contents spend in the lower bowel enables increased water and electrolyte reabsorption by the intestinal lining. This results in altered fluid transport across the intestinal wall, producing contents with decreased fluid volume and increased viscosity.

Dosage and Administration Information

How to Use Lomotil Oral Solution (Diphenoxylate and Atropine)

These instructions outline administration guidelines for the medication.

Administration and Dosage

Route of Administration: Oral.

Initial Dosing and Frequency:

Age Group Initial Dose (Diphenoxylate HCl Equivalent) Frequency
Adults and children ge 13 years 5 mg (10 mL of solution) Four times daily
Children 2 to 12 years Weight-based dosing in divided doses As prescribed

Maintenance Schedule: The dosage must be reduced immediately as soon as symptoms are initially controlled. Maintenance may often be sustained with a significantly lower daily amount, sometimes as little as 5 mg (10 mL) daily. The maximum recommended daily dosage is 20 mg (40 mL of solution).

Procedural Requirements

Measurement: The oral solution must be measured precisely using a calibrated measuring device, such as a marked spoon, oral syringe, or medicine cup. Household spoons should not be used.

Special Conditions: The medicine must be used only as an adjunct to appropriate fluid and electrolyte replacement therapy. If severe dehydration or electrolyte imbalance is present, the medicine should be withheld until corrective therapy has been initiated.

Treatment Duration: If clinical improvement is not observed within 10 days while taking the maximum recommended daily dosage, the drug must be discontinued.

Age Restrictions: Only the oral solution is indicated for children 2 to 12 years of age. Use is generally contraindicated for children under 6 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Lomotil Solution


Evidence for the Symptomatic Control of General Diarrhea (Acute and Chronic)

The clinical research for this solution includes established Randomized Controlled Trials (RCTs) and systematic reviews that explored the medicine in the context of symptom relief for general diarrhea. This evidence base primarily addressed conditions characterized by fluctuating or episodic manifestations, such as non-specific acute diarrhea and Traveler’s Diarrhea. Studies focused on outcomes monitoring physiological strain or stress and outcomes related to physical discomfort.

Research examined both adults and adolescents, monitoring their symptoms over short-term follow-up periods, such as 48 hours to one week. The main outcomes studied included measurements of stool frequency and assessing stool consistency. However, comparative evidence is lacking regarding how this solution was observed against newer or standard antidiarrheal treatments in current, large-scale RCTs. The evidence quality varies across studies.

Evidence for Diarrhea in Specific or Complex Patient Contexts

Research also explored the use of this medication in patients with more challenging clinical situations, which are conditions involving periods of heightened symptoms. These scenarios include studies conducted in critically ill adults and in adult patients with cancer facing diarrhea related to chemotherapy and/or radiation (CRT-ID). Studies monitoring these groups focused on outcomes capturing phases of heightened symptom activity, such as the time it took for diarrhea to resolve or changes in the severity grade of the condition.

However, for these complex contexts, evidence is limited and the certainty remains low. The research base includes only a limited number of dedicated controlled trials in these high-acuity groups, and many studies involved modest sample sizes or observational settings, meaning the results apply only to the populations studied.

What Remains Unclear About the Research Evidence

The available evidence base describes what has been observed so far, but several gaps and uncertainties exist. Long-term effects are not fully established, and there is limited information for long-term outcomes or the continued presence of observed changes. Additionally, the research base does not determine the safety or efficacy in managing diarrhea resulting from specific severe bacterial infections. A major point of clarity is that clinical evaluation is not established in children younger than 13 years old.

Key Studies & References Class Review: Antidiarrheals - OHP Preferred Drug List (Source for lack of comparative evidence and specific contraindications)

Frequently Asked Questions (FAQ)

Common questions about Lomotil Solution (FAQ)

Q: How quickly does Lomotil Solution start working after taking it?

Official product information indicates that the onset of action is typically observed within 45 minutes to 1 hour after the oral dose. While the medicine begins acting quickly, significant improvement in diarrhea symptoms is generally expected within the first 48 hours of starting the prescribed treatment course.


Q: How long do the effects of Lomotil Solution typically last?

According to product documentation, the effects of a single dose of the solution generally last for approximately 3 to 4 hours. This duration is consistent with the established intervals for taking the medicine.


Q: What happens if I miss a dose of Lomotil Solution?

Official patient information describes taking a dose as soon as it is remembered. If it is already close to the time for the next scheduled dose, the regulatory guidelines describe skipping the missed dose entirely. Patients are cautioned not to double the dose to compensate for the one they missed.


Q: Is the liquid form of Lomotil easier to absorb than a tablet?

Official studies on the body’s processing of the drug show that the bioavailability of the tablet form is about 90% of the oral solution. The solution form is frequently available to facilitate easier administration, particularly for children or individuals who may have difficulty swallowing tablets.


Q: What is the difference between Lomotil and its generic version?

Lomotil is the original brand-name formulation of this medicine. The generic version contains the identical active pharmaceutical ingredients: diphenoxylate hydrochloride and atropine sulfate. In many cases, the oral liquid solution is often available only in its generic form.


Q: Are there any common foods or drinks that interact with Lomotil Solution?

Regulatory documents indicate that the solution can be taken with or without food; consuming it with food may help minimize stomach discomfort. Official labeling states that the use of alcohol should be avoided or limited due to the risk of increased side effects affecting the nervous system.


Q: What happens to the ingredients of Lomotil Solution in the body?

After taking the solution, the active ingredient diphenoxylate is processed by the body’s liver, where it is broken down into an active metabolite called difenoxin. The initial concentration of diphenoxylate in the bloodstream typically peaks approximately two hours after oral administration.


Q: Are there any long-term side effects associated with using Lomotil Solution?

Official product information indicates that this medicine is typically prescribed for short-term use. This is reflected in the official instruction that if clinical improvement is not seen within 10 days, the drug must be discontinued. Long-term effects and outcomes are not fully established in available research.


Q: Does Lomotil Solution cause drowsiness or affect driving ability?

The regulatory label notes that the medication can cause side effects related to Central Nervous System (CNS) depression, such as drowsiness and dizziness. Official warnings state that activities requiring high mental alertness, such as operating dangerous machinery or driving, should be avoided due to this risk.


Q: Does Lomotil Solution interact with antidepressant medications?

Official drug interaction information specifies that Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressants, are formally contraindicated due to a theoretical risk of a hypertensive crisis. Additionally, the drug may enhance the effects of other medicines that cause drowsiness or dizziness, which can include certain other antidepressant classes.


Q: Can I take Lomotil Solution if I have an existing heart condition?

The atropine component of the solution has been associated with effects on the cardiovascular system, including tachycardia (rapid heart rate) and palpitations. Regulatory constraints suggest that individuals with pre-existing heart conditions should seek consultation regarding these potential risks.


Q: Is there a risk of becoming dependent on Lomotil Solution?

As the main active ingredient possesses opioid properties, the medication is classified as a Controlled Substance. Reports of physical and psychological dependence have been noted, typically when the drug is taken at doses exceeding the official recommendations.


Q: Does Lomotil Solution cause constipation?

The medicine functions by significantly slowing down intestinal movement to control diarrhea. While constipation itself is not consistently listed as a common effect, regulatory documents do include the risk of paralytic ileus—a severe type of bowel obstruction that can result from decreased intestinal propulsion.


Q: What are the signs that I should stop taking Lomotil Solution?

Official safety information indicates two main reasons for prompt discontinuation. Regulatory documents describe that the drug should be promptly discontinued if a patient experiences abdominal distention, particularly if they have acute ulcerative colitis. Treatment must also be discontinued if there is no observed clinical improvement in diarrhea symptoms after 10 days of use.


Q: Does Lomotil Solution interact with muscle relaxants?

Official product information states that diphenoxylate hydrochloride may potentiate the action of other medicines that cause dizziness or drowsiness. This includes certain muscle relaxants, and the combination can lead to an additive depressant effect on the central nervous system.


Q: Does Lomotil Solution work by killing bacteria in the gut?

No, the medicine is classified as an antiperistaltic agent; its action is to slow down gut motility and transit time. It is important to note that the drug is formally contraindicated (prohibited) in diarrhea caused by specific bacteria, as slowing movement may potentially worsen the condition by enhancing bacterial overgrowth and the release of toxins.

How should Lomotil Solution be stored and disposed of?

Lomotil oral solution must be stored in a closed, child-resistant container at controlled room temperature, maintaining 20 C to 25 C (68 F to 77 F). The medication must be protected from freezing, heat, moisture, and light. Due to the severe risk of accidental ingestion, it is a mandatory requirement to store the solution securely and out of the sight and reach of children.

As a controlled substance, the product must be stored safely. The official labeled stability constraint is to discard any unused solution 90 days after the initial opening. Unused or expired Lomotil must be properly disposed of; patients should consult a healthcare professional or pharmacist for specific instructions regarding disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lomotil Solution found in:

A-Z Index: